TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01627795
Drug: Oshadi D and Oshadi R
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti cancer agents
Study: NCT04598295
Drug: DS-01
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: synbiotic
Study: NCT03485703
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
Study: NCT03485703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the group of newborns will receive 0.9% saline once daily for 5 days
Study: NCT00802958
Drug: Halobetasol Propionate 0.05% Ointment-Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of a day
Study: NCT00802958
Drug: Halobetasol Propionate 0.05% Ointment-Test Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of a day
Study: NCT02787083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00182533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 - 200 mg/day x 16 weeks
Study: NCT00003513
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00312052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg and/or 100 mg placebo tablets
Study: NCT00652717
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Study: NCT02547896
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will receive only diclofenac
Study: NCT01612078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg/tab, po, three times a week.
Study: NCT03277716
Drug: Chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
Study: NCT03891823
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
Study: NCT02735473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00857961
Drug: Testosterone MD-Lotion
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Topically
Study: NCT02226120
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Study: NCT04272957
Drug: HMPL-306
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study: NCT03285165
Drug: 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
Study: NCT04418089
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
Study: NCT04418089
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
Study: NCT01905592
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
Study: NCT03034135
Drug: Disulfiram/Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram/copper gluconate is taken three times a day.
Study: NCT01897519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT02859519
Drug: MOB015B
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
Study: NCT02859519
Drug: MOB015B Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOB015B Vehicle without the active ingredient Terbinafine
Study: NCT04137341
Drug: GLPG1972 - A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet, formulation A
Study: NCT04137341
Drug: GLPG1972 - B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet, formulation B
Study: NCT02870764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT02530918
Drug: DS-7080a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
Study: NCT02324621
Drug: Oral ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00817505
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral tablet
Study: NCT00817505
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral suspension
Study: NCT00565097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02421939
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Normalized name: CATHETER,EXTERNAL MALE QIVI MEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection
Study: NCT03280745
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
Study: NCT03280745
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Study: NCT02227368
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Study: NCT01160380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
Study: NCT00300846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
Study: NCT04136262
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study: NCT01663857
Drug: LY2228820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT01663857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT01421147
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT02751619
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
Study: NCT00034047
Drug: Chinese Products
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05229627
Drug: ATX
Normalized name: Diatx
Approvals — FDA: no, EMA: no, PMDA: no
Description: the drug would be prescribed to patients without any contraindication
Study: NCT00063297
Drug: R209130
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03307837
Drug: CA-008
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration during surgery
Study: NCT03307837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local administration during surgery
Study: NCT04100655
Drug: 17-ß estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
Study: NCT02732015
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01156883
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01156883
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01156883
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01156883
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00943501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
Study: NCT00943501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
Study: NCT04544163
Drug: Magnesium sulfate- Fentanyl
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug administration before intubation
Study: NCT04544163
Drug: Fentanyl 4Mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug administration with induction of anesthesia
Study: NCT04544163
Drug: Fentanyl 2Mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug administration with induction of anesthesia
Study: NCT02301845
Drug: Diatoms Shells
Normalized name: egg shell membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of suspended diatom shells - 10 mg q12h
Study: NCT02171832
Drug: BI 1744 CL, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02171832
Drug: BI 1744 CL, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03664921
Drug: Omnitram Oral Tablet
Normalized name: Orenitram Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered three times daily for 28 consecutive days.
Study: NCT03664921
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered three times daily for 28 consecutive days.
Study: NCT02362425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00824707
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy including protecting the liver function, anti-tumor and so on
Study: NCT00525876
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
Study: NCT00596453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 14 days
Study: NCT01313221
Drug: Topical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%
Study: NCT00719394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03231137
Drug: ATV gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin gel
Study: NCT00333632
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02844894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT01031017
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02217800
Drug: DG3173
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Study: NCT01754766
Drug: AGN-229666
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-229666 into each eye on Day 1 and Day 15.
Study: NCT01967979
Drug: RO5285119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, alone and after repeated administration of itraconazole or fluoxetine
Study: NCT01967979
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses
Study: NCT00433017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Study: NCT01793350
Drug: BC-DN-01 topically applied cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
Study: NCT03627715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04112550
Drug: Oxycodone-Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved medication to treat pain
Study: NCT03972501
Drug: AZR-MD-001 Active Dose
Normalized name: eptacog alfa activated 0.001 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is an ophthalmic ointment
Study: NCT01342445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01873157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11.
Study: NCT04193553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.
Study: NCT00802672
Drug: Loprox Cream 0.77%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream
Study: NCT00802672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream
Study: NCT00394394
Drug: Amiloride 2,5/d or Enalapril/d 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01319487
Drug: Placebo Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Eye Drops self-administered in the study eye during the treatment period
Study: NCT00214656
Drug: Recombinant Activated Factor VII
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01241331
Drug: BLI1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI110 topical cream
Study: NCT01241331
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical cream
Study: NCT02081014
Drug: G-Pen Mini™ (glucagon injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection
Study: NCT02875873
Drug: Plasma-Lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-Lyte will be used for fluid expansion and maintenance
Study: NCT02875873
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% will be used for fluid expansion and maintenance
Study: NCT00176514
Drug: Administration of the antineoplastic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03033160
Drug: Estradiol Ring
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06365190
Drug: Pharmacotherapy（antiparkinsonian drugs）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
Study: NCT02799888
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
Study: NCT00514982
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Corticosteroid used to treat inflammatory conditions.
Study: NCT01548768
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.
Study: NCT01548768
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
Study: NCT00290693
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
Study: NCT01515566
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
Study: NCT00003902
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00560703
Drug: COL-101 (doxycycline, USP) capsules
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg, once per day for 84 days
Study: NCT00560703
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar capsule
Study: NCT00258193
Drug: MD-1100 Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03927326
Drug: Exparel 266 MG Per 20 ML Injection
Normalized name: Exparel 266 MG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine
Study: NCT04394663
Drug: Standard IV PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
Study: NCT01979601
Drug: LGT209
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lyophilized powder in glass vial
Study: NCT01979601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03421275
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous fentanyl given intranasally
Study: NCT02265939
Drug: NPO-13
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03616392
Drug: D308, CKD-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg
Study: NCT00647036
Drug: Dipeptiven (L-glutamine- Lalanine)
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6g/kg/day
Study: NCT02540161
Drug: Sym004 - 18 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 was dosed at 18 mg/kg intravenously every two weeks.
Study: NCT01043484
Drug: Capecitabine + Radiotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
Study: NCT04231968
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
Study: NCT04231968
Drug: Matching placebo of AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Study: NCT02324699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03183479
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL normal saline will be administered to patients in control group as placebo